CR8108A - Tratamiento con anticuerpos anti-vegf - Google Patents
Tratamiento con anticuerpos anti-vegfInfo
- Publication number
- CR8108A CR8108A CR8108A CR8108A CR8108A CR 8108 A CR8108 A CR 8108A CR 8108 A CR8108 A CR 8108A CR 8108 A CR8108 A CR 8108A CR 8108 A CR8108 A CR 8108A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- vegf antibodies
- vegf
- relates
- diagnosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion se refiere en general al tratamiento de enfermedades y condiciones patologicas con anticuerpos anti-VEGF. Mas especificamente, la invencion se refiere al tratamiento de pacientes humanos susceptibles a que se les diagnostica cancer utilizando un anticuerpo anti-VEGF, de preferencia en combinacion con uno o mas agentes terapeuticos anti-tumor adicionales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47448003P | 2003-05-30 | 2003-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8108A true CR8108A (es) | 2007-06-20 |
Family
ID=33551495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8108A CR8108A (es) | 2003-05-30 | 2005-11-30 | Tratamiento con anticuerpos anti-vegf |
Country Status (23)
Country | Link |
---|---|
US (41) | US20050186208A1 (es) |
EP (4) | EP2311875A1 (es) |
JP (8) | JP2007525466A (es) |
KR (11) | KR20120104408A (es) |
CN (2) | CN1829741A (es) |
AU (2) | AU2004251168A1 (es) |
BR (1) | BRPI0411200A (es) |
CA (1) | CA2526085A1 (es) |
CO (1) | CO5640150A2 (es) |
CR (1) | CR8108A (es) |
EC (1) | ECSP056187A (es) |
IL (4) | IL171833A (es) |
MA (1) | MA27854A1 (es) |
ME (1) | ME00425B (es) |
MX (1) | MXPA05012723A (es) |
NO (1) | NO20056236L (es) |
NZ (1) | NZ621449A (es) |
RS (5) | RS20170595A1 (es) |
RU (4) | RU2005136988A (es) |
TN (1) | TNSN05300A1 (es) |
UA (1) | UA101945C2 (es) |
WO (1) | WO2005000900A1 (es) |
ZA (1) | ZA200509059B (es) |
Families Citing this family (255)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
CN102516417B (zh) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
KR20120104408A (ko) * | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
CA3054535A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
EP1870459B1 (en) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
AU2006272343B2 (en) * | 2005-07-21 | 2012-09-13 | Nuvo Research Ag | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
US8023114B2 (en) | 2005-08-01 | 2011-09-20 | Canon Kabushiki Kaisha | Target substance detecting device, target substance detecting method using the same, and detecting apparatus and kit therefor |
JP4878238B2 (ja) * | 2005-08-01 | 2012-02-15 | キヤノン株式会社 | 標的物質検出用の素子及びそれを用いた標的物質の検出方法、並びにそのための検出装置及びキット |
WO2007022101A2 (en) * | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
KR101643416B1 (ko) | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
PL3311805T3 (pl) | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
EP1957536A2 (en) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
CA2647430A1 (en) * | 2006-03-29 | 2007-10-11 | Genentech, Inc. | Diagnostics and treatments for tumors |
DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
JP5796267B2 (ja) * | 2006-04-10 | 2015-10-21 | フージョン アンティボディーズ リミテッド | 治療法 |
US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
JP2009537606A (ja) * | 2006-05-25 | 2009-10-29 | ノバルティス アクチエンゲゼルシャフト | チロシンキナーゼ阻害剤 |
TW200817435A (en) * | 2006-06-06 | 2008-04-16 | Genentech Inc | Compositions and methods for modulating vascular development |
AU2007319672B2 (en) * | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
CA2655411A1 (en) * | 2006-06-15 | 2007-12-21 | Biogen Idec Ma Inc. | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
US20080050385A1 (en) | 2006-08-21 | 2008-02-28 | Thomas Friess | Tumor therapy with an anti-vegf antibody |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
SI2101807T1 (sl) | 2006-12-19 | 2016-08-31 | Genentech, Inc. | VEGF-specifični antagonisti za adjuvansno in neoadjuvansno terapijo in zdravljenje tumorjev v zgodnjem stadiju |
AU2014201795B2 (en) * | 2006-12-19 | 2016-05-19 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
TW200838875A (en) * | 2007-02-01 | 2008-10-01 | Genentech Inc | Combination therapy with angiogenesis inhibitors |
WO2008149147A2 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
CL2008002782A1 (es) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
US11331294B2 (en) | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
US9089605B2 (en) | 2007-09-26 | 2015-07-28 | Indiana University Research And Technology Corporation | Quinone derivatives, pharmaceutical compositions, and uses thereof |
HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
US8216571B2 (en) * | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
AU2008324789A1 (en) | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist compositions and methods of use |
AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
MX2010007101A (es) | 2007-12-26 | 2011-07-01 | Biotest Ag | Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138. |
US8580755B2 (en) * | 2008-02-19 | 2013-11-12 | University Of Rochester | Methods and compositions for treating inflammatory conditions |
US20110159080A1 (en) * | 2008-06-03 | 2011-06-30 | Colin Lowery | Composition comprising liposome-entrapped doxorubicin and methods of administration |
EP3216803B1 (en) | 2008-06-25 | 2020-03-11 | Novartis Ag | Stable and soluble antibodies inhibiting vegf |
ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
WO2010010153A1 (en) * | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Identification of subjects being susceptible to anti-angiogenesis therapy |
EP2324358A1 (en) * | 2008-07-23 | 2011-05-25 | F. Hoffmann-La Roche AG | Monitoring anti-angiogenesis therapy |
KR20110068987A (ko) * | 2008-08-29 | 2011-06-22 | 제넨테크, 인크. | Vegf-비의존적 종양의 진단 및 치료 |
WO2010027981A1 (en) | 2008-09-03 | 2010-03-11 | Genentech, Inc. | Multispecific antibodies |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
PE20110707A1 (es) | 2008-10-14 | 2011-10-11 | Genentech Inc | Variantes de inmunoglobulinas |
AU2009316409A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
US20100143290A1 (en) * | 2008-12-04 | 2010-06-10 | Lallatin Nathaniel C | Monoclonal antibodies to human thymidine kinase to treat cancer |
KR20140020368A (ko) | 2008-12-23 | 2014-02-18 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
EP3517961B1 (en) * | 2009-01-09 | 2020-12-30 | Oxford BioMedica (UK) Limited | Factors |
WO2010091234A2 (en) | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
MX2011009729A (es) | 2009-03-20 | 2011-10-14 | Genentech Inc | Anticuerpos anti-her. |
SG175004A1 (en) | 2009-04-02 | 2011-11-28 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
WO2010115589A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Trivalent, bispecific antibodies |
MX2011010955A (es) * | 2009-04-20 | 2012-04-02 | Genentech Inc | Terapia complementaria contra el cancer. |
AU2010245668B2 (en) | 2009-05-08 | 2016-07-14 | Vaccinex, Inc. | Anti-CD100 antibodies and methods for using the same |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
ES2534355T3 (es) * | 2009-06-17 | 2015-04-21 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-VEGF y sus usos |
JP6095367B2 (ja) | 2009-07-13 | 2017-03-15 | ジェネンテック, インコーポレイテッド | 癌治療のための診断方法および組成物 |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
EP2459591B1 (en) * | 2009-07-31 | 2014-08-20 | Genentech, Inc. | Inhibition of tumor metastasis using anti-g-csf-antibodies |
CN102573909A (zh) * | 2009-08-15 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | 抗血管发生疗法用于治疗先前治疗过的乳腺癌 |
EP2722055A1 (en) * | 2009-08-17 | 2014-04-23 | Tracon Pharmaceuticals, Inc. | Combination therapy with antibodies and anti-VEGF agents for the treatment of cancer |
US20180057602A1 (en) * | 2009-08-17 | 2018-03-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
WO2011028642A1 (en) | 2009-09-04 | 2011-03-10 | University Of Louisville Research Foundation, Inc. | Genetic determinants of prostate cancer risk |
CN102597776A (zh) | 2009-09-11 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌剂的可能性升高的患者的方法 |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
CN102612566B (zh) | 2009-09-17 | 2016-02-17 | 霍夫曼-拉罗奇有限公司 | 用于癌症患者中诊断学用途的方法和组合物 |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
EP2493458A2 (en) * | 2009-10-30 | 2012-09-05 | The Ohio State University | Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
US8968740B2 (en) * | 2009-11-13 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
ES2565208T3 (es) | 2009-12-11 | 2016-04-01 | F. Hoffmann-La Roche Ag | Anticuerpos anti-VEGF-C y métodos de uso de los mismos |
RU2609658C2 (ru) | 2009-12-21 | 2017-02-02 | Дженентек, Инк. | Состав, содержащий антитело |
CN103068849B (zh) | 2009-12-23 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗Bv8抗体及其用途 |
RU2012140447A (ru) | 2010-02-23 | 2014-03-27 | Дженентек, Инк. | Антиангиогенная терапия для лечения рака яичника |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
EP2552415B1 (en) | 2010-03-29 | 2016-09-07 | Abraxis BioScience, LLC | Methods of treating cancer |
ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
WO2012010549A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
KR20130091745A (ko) | 2010-07-19 | 2013-08-19 | 에프. 호프만-라 로슈 아게 | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 |
EP2596026B1 (en) | 2010-07-23 | 2020-04-08 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
AR082693A1 (es) | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf |
CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
JP5945277B2 (ja) | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Fgfr1細胞外ドメイン併用療法 |
TW202323302A (zh) | 2010-11-30 | 2023-06-16 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EP2670776B1 (en) | 2011-02-04 | 2018-11-21 | F. Hoffmann-La Roche AG | Fc VARIANTS AND METHODS FOR THEIR PRODUCTION |
RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
HUE036513T2 (hu) | 2011-04-01 | 2018-07-30 | Genentech Inc | AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra |
CN108341863A (zh) | 2011-04-20 | 2018-07-31 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
WO2012151317A1 (en) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Vascular disruption agents and uses thereof |
JP6067686B2 (ja) * | 2011-06-02 | 2017-01-25 | アルマック ダイアグノスティックス リミテッド | 癌の分子的診断検査 |
WO2012167122A1 (en) | 2011-06-03 | 2012-12-06 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
CA2835242A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
MX2014001736A (es) | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
CA2849508C (en) * | 2011-09-30 | 2020-12-22 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
WO2013063679A1 (en) * | 2011-11-04 | 2013-05-10 | Josefowitz Paul Zachary | Use of neul sialidase inhibitors in the treatment of cancer |
CA2854477A1 (en) | 2011-11-21 | 2013-05-30 | Genentech, Inc. | Purification of anti-c-met antibodies |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
JP6486686B2 (ja) | 2012-02-10 | 2019-03-20 | ジェネンテック, インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
PT2825558T (pt) | 2012-03-13 | 2019-07-11 | Hoffmann La Roche | Terapêutica combinada para o tratamento do cancro do ovário |
KR20190134832A (ko) * | 2012-03-29 | 2019-12-04 | 알토 바이오사이언스 코포레이션 | 종양 형성 치료방법 |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
CN103417965B (zh) * | 2012-05-17 | 2018-04-13 | 江苏先声药业有限公司 | 一种含有抗vegf抗体的药物组合物 |
RU2711089C2 (ru) * | 2012-05-18 | 2020-01-15 | Дженентек, Инк. | Высококонцентрированные составы моноклональных антител |
BR112014029887A8 (pt) | 2012-05-31 | 2021-09-14 | Genentech Inc | Método para tratar ou retardar a progressão do câncer, kits e uso de um antagonista de ligação do eixo pd-1, oxaliplatina, leucovorina e 5-fu |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
CA2871882A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
RU2636348C2 (ru) | 2012-07-05 | 2017-11-22 | Ваксимм Аг | Днк-вакцина для применения у пациентов с раком поджелудочной железы |
RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
KR20190088571A (ko) | 2012-08-07 | 2019-07-26 | 제넨테크, 인크. | 교모세포종의 치료를 위한 조합 요법 |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
CA2893033A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
CA2930987A1 (en) | 2013-01-11 | 2014-07-17 | Massachusetts Eye And Ear Infirmary | Cyp450 lipid metabolites reduce inflammation and angiogenesis |
US9500464B2 (en) * | 2013-03-12 | 2016-11-22 | Adidas Ag | Methods of determining performance information for individuals and sports objects |
BR112015022210A8 (pt) | 2013-03-13 | 2018-01-23 | Genentech Inc | formulações de anticorpo |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US9440963B2 (en) * | 2013-03-15 | 2016-09-13 | Aerpio Therapeutics, Inc. | Compositions, formulations and methods for treating ocular diseases |
ES2759061T3 (es) | 2013-03-15 | 2020-05-07 | Biomolecular Holdings Llc | Inmunoglobulina híbrida que contiene unión no peptidílica |
MX2015015426A (es) | 2013-05-23 | 2016-06-10 | Five Prime Therapeutics Inc | Metodos de tratamiento de cancer. |
KR101541478B1 (ko) * | 2013-05-31 | 2015-08-05 | 동아쏘시오홀딩스 주식회사 | 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물 |
DK3013350T3 (da) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
CN104341504B (zh) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
EP3055329B1 (en) | 2013-10-11 | 2018-06-13 | F. Hoffmann-La Roche AG | Multispecific domain exchanged common variable light chain antibodies |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
KR20220013459A (ko) | 2013-10-25 | 2022-02-04 | 악셀레론 파마 인코포레이티드 | 섬유화 질환을 치료하기 위한 엔도글린 펩티드 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
SI3116909T1 (sl) | 2014-03-14 | 2020-03-31 | Novartis Ag | Molekule protiteles na LAG-3 in njih uporaba |
KR102475799B1 (ko) | 2014-03-14 | 2022-12-08 | 다니엘 제이 카폰 | 비-펩티드 결합을 함유하는 하이브리드 면역글로불린 |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
AU2015241038A1 (en) | 2014-03-31 | 2016-10-13 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists |
US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
EP4306544A3 (en) | 2014-05-06 | 2024-03-20 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins using mammalian cells |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
JP6800141B2 (ja) | 2014-08-12 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置 |
WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
CN108064182B (zh) | 2014-09-09 | 2021-09-03 | 詹森生物科技公司 | 采用抗cd38抗体的联合疗法 |
CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
MX2017003121A (es) | 2014-09-15 | 2017-08-02 | Genentech Inc | Formulaciones de anticuerpos. |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
CN107172879B (zh) | 2014-11-10 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 抗白细胞介素-33抗体及其用途 |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
AU2015369624A1 (en) | 2014-12-23 | 2017-06-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
HUE037698T2 (hu) * | 2014-12-30 | 2018-09-28 | Curadis Gmbh | C-19 szteroidok neovaszkularizáció gátlására |
EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER |
AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
EP4219561A3 (en) | 2015-05-20 | 2023-11-08 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
AU2016274584A1 (en) | 2015-06-08 | 2018-01-04 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists |
EP3310386B1 (en) | 2015-06-22 | 2021-07-21 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Pd−1に対する抗体分子を含む組み合わせ治療 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
CA2992789A1 (en) | 2015-08-20 | 2017-02-23 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
JP2018528185A (ja) | 2015-08-21 | 2018-09-27 | イプセン バイオファーム リミティド | リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法 |
KR102700777B1 (ko) | 2015-09-17 | 2024-08-29 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
TWI748962B (zh) | 2015-09-23 | 2021-12-11 | 美商建南德克公司 | 抗vegf抗體之最佳化變異體 |
US10421821B2 (en) | 2015-10-30 | 2019-09-24 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use thereof |
MA43187B1 (fr) | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
CR20180234A (es) | 2015-11-03 | 2018-09-11 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
CN109154613A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
JP2019515670A (ja) | 2016-04-15 | 2019-06-13 | ジェネンテック, インコーポレイテッド | がんをモニタリングし治療するための方法 |
EP3482205A1 (en) | 2016-07-08 | 2019-05-15 | H. Hoffnabb-La Roche Ag | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
CN109890982B (zh) | 2016-07-08 | 2023-07-07 | 基因泰克公司 | 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法 |
MA46709A (fr) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Ltd | Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale |
CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
WO2018132516A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
MA49457A (fr) | 2017-06-22 | 2020-04-29 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
CN111511400A (zh) | 2017-12-29 | 2020-08-07 | 豪夫迈·罗氏有限公司 | 抗vegf抗体及其使用方法 |
CN113975264A (zh) | 2018-04-16 | 2022-01-28 | 上海岸阔医药科技有限公司 | 预防或治疗肿瘤疗法副作用的方法 |
EA202092839A1 (ru) | 2018-05-24 | 2021-02-12 | Янссен Байотек, Инк. | Агенты, связывающиеся с psma, и виды их применения |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EP3814381A4 (en) | 2018-06-29 | 2022-08-10 | Gensun Biopharma Inc. | TRI-SPECIFIC ANTAGONISTS |
CN113196061A (zh) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
TWI844571B (zh) * | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
CN113747944A (zh) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | 用抗psma/cd3抗体治疗前列腺癌的方法 |
EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
CN112010971A (zh) * | 2019-05-30 | 2020-12-01 | 义慧科技(深圳)有限公司 | 抗vegf抗体在制备预防和/或治疗脂肪肝的药物中的应用 |
JP2022540571A (ja) | 2019-06-28 | 2022-09-16 | ゲンスン バイオファーマ、インコーポレーテッド | 変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト |
EP4001306A4 (en) | 2019-07-19 | 2023-11-15 | Sinocelltech Ltd. | HUMANIZED MONOCLONAL ANTIBODY AGAINST VEGF |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
MX2022011156A (es) | 2020-03-13 | 2022-10-13 | Genentech Inc | Anticuerpos anti-interleucina-33 y usos de estos. |
EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
MX2023005529A (es) | 2020-11-13 | 2023-05-25 | Genentech Inc | Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos. |
WO2022157715A1 (en) | 2021-01-22 | 2022-07-28 | Dcprime B.V. | Methods of tumor vaccination |
PE20240761A1 (es) | 2021-01-28 | 2024-04-17 | Janssen Biotech Inc | Proteinas de union a psma y usos de estas |
JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びcd47遮断薬の使用 |
KR20220141572A (ko) | 2021-04-13 | 2022-10-20 | 김문재 | 확장형 실내 캠핑실이 삽입 및 인출되는 차량 |
EP4330436A1 (en) | 2021-04-30 | 2024-03-06 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
US20240279324A1 (en) | 2021-06-03 | 2024-08-22 | Gensun Biopharma Inc. | Multispecific antagonists |
CN115814076A (zh) * | 2021-07-01 | 2023-03-21 | 江苏先声药业有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
TW202309078A (zh) | 2021-07-02 | 2023-03-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
MX2024001214A (es) | 2021-07-28 | 2024-02-12 | Hoffmann La Roche | Metodos y composiciones para tratar cancer. |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2023144973A1 (ja) | 2022-01-27 | 2023-08-03 | 中外製薬株式会社 | 抗vegf抗体及びパクリタキセルと組み合わせて使用する抗pd-l1抗体を含む医薬組成物 |
CN118742325A (zh) | 2022-01-28 | 2024-10-01 | 上海岸阔医药科技有限公司 | 预防或治疗与抗肿瘤剂相关的疾病或病症的方法 |
WO2023155905A1 (zh) | 2022-02-21 | 2023-08-24 | 上海岸阔医药科技有限公司 | 化合物及其用途 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5036003A (en) | 1987-08-21 | 1991-07-30 | Monsanto Company | Antibodies to VPF |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ATE221915T1 (de) | 1991-02-22 | 2002-08-15 | American Cyanamid Co | Identifizierung eines menschlichen rezeptor- tyrosinkinasegens |
OA10149A (en) | 1991-03-29 | 1996-12-18 | Genentech Inc | Vascular endothelial cell growth factor antagonists |
US20010021382A1 (en) | 1991-03-29 | 2001-09-13 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US20020032313A1 (en) | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20060193862A1 (en) | 1995-03-30 | 2006-08-31 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
SI2275119T1 (sl) | 1995-07-27 | 2013-12-31 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
JPH10114680A (ja) | 1996-10-08 | 1998-05-06 | Toagosei Co Ltd | 制癌剤 |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
NZ500078A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
BRPI9809388B8 (pt) | 1997-04-07 | 2021-05-25 | Genentech Inc | anticorpos humanizados e métodos para a formação de anticorpos humanizados. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US20150023951A1 (en) | 1997-04-07 | 2015-01-22 | Genentech, Inc. | Anti-vegf antibodies |
DK1860187T3 (da) | 1997-05-15 | 2011-10-31 | Genentech Inc | Apo-2-receptor |
WO1999037684A1 (en) | 1998-01-26 | 1999-07-29 | Genentech, Inc. | Antibodies to death receptor 4 (dr4) and uses thereof |
IL143596A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
EP1140198B1 (en) | 1999-01-13 | 2007-10-31 | Alchemia Oncology Pty Limited | Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs |
US6342221B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
RU2177349C1 (ru) | 2001-02-20 | 2001-12-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ | Способ лечения инфильтративно-отечного рака молочной железы |
WO2003075741A2 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
CN1187373C (zh) | 2002-03-20 | 2005-02-02 | 上海中信国健药业有限公司 | 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物 |
KR20120104408A (ko) | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US20070036755A1 (en) | 2004-05-28 | 2007-02-15 | Genentech, Inc. | Treatment with anti-vegf antibodies |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
-
2004
- 2004-05-28 KR KR1020127020254A patent/KR20120104408A/ko not_active Application Discontinuation
- 2004-05-28 RS RS20170595A patent/RS20170595A1/sr unknown
- 2004-05-28 KR KR1020117024530A patent/KR20110118738A/ko not_active Application Discontinuation
- 2004-05-28 RU RU2005136988/14A patent/RU2005136988A/ru not_active Application Discontinuation
- 2004-05-28 AU AU2004251168A patent/AU2004251168A1/en not_active Abandoned
- 2004-05-28 CN CNA2004800219668A patent/CN1829741A/zh active Pending
- 2004-05-28 CN CNA2008100916811A patent/CN101274098A/zh active Pending
- 2004-05-28 KR KR1020147034380A patent/KR20150008458A/ko not_active Application Discontinuation
- 2004-05-28 ZA ZA200509059A patent/ZA200509059B/en unknown
- 2004-05-28 UA UAA200902354A patent/UA101945C2/uk unknown
- 2004-05-28 RS RS20181002A patent/RS20181002A1/sr unknown
- 2004-05-28 BR BRPI0411200-8A patent/BRPI0411200A/pt not_active Application Discontinuation
- 2004-05-28 KR KR1020197019735A patent/KR20190085166A/ko not_active Application Discontinuation
- 2004-05-28 EP EP10010292A patent/EP2311875A1/en not_active Ceased
- 2004-05-28 US US10/857,249 patent/US20050186208A1/en not_active Abandoned
- 2004-05-28 EP EP10007446A patent/EP2251355A1/en not_active Withdrawn
- 2004-05-28 NZ NZ621449A patent/NZ621449A/en not_active IP Right Cessation
- 2004-05-28 KR KR1020057022821A patent/KR20060006975A/ko not_active Application Discontinuation
- 2004-05-28 JP JP2006515027A patent/JP2007525466A/ja active Pending
- 2004-05-28 KR KR1020187003240A patent/KR20180014881A/ko not_active Application Discontinuation
- 2004-05-28 KR KR1020167001734A patent/KR20160014775A/ko not_active Application Discontinuation
- 2004-05-28 WO PCT/US2004/017078 patent/WO2005000900A1/en active Application Filing
- 2004-05-28 RS RS20150135A patent/RS20150135A1/en unknown
- 2004-05-28 MX MXPA05012723A patent/MXPA05012723A/es active IP Right Grant
- 2004-05-28 KR KR1020187034952A patent/KR20180132969A/ko not_active Application Discontinuation
- 2004-05-28 KR KR1020167025546A patent/KR20160114727A/ko not_active Application Discontinuation
- 2004-05-28 KR KR1020177015008A patent/KR20170073698A/ko not_active Application Discontinuation
- 2004-05-28 EP EP04753820A patent/EP1629010A1/en not_active Withdrawn
- 2004-05-28 CA CA002526085A patent/CA2526085A1/en not_active Abandoned
- 2004-05-28 RS RS20160203A patent/RS20160203A1/sr unknown
- 2004-05-28 RS YUP-2005/0885A patent/RS20050885A/sr unknown
- 2004-05-28 ME MEP-2008-635A patent/ME00425B/me unknown
- 2004-05-28 KR KR1020207008184A patent/KR20200034817A/ko not_active Application Discontinuation
- 2004-05-28 EP EP10007445A patent/EP2248829A1/en not_active Withdrawn
-
2005
- 2005-11-08 IL IL171833A patent/IL171833A/en not_active IP Right Cessation
- 2005-11-23 TN TNP2005000300A patent/TNSN05300A1/en unknown
- 2005-11-25 EC EC2005006187A patent/ECSP056187A/es unknown
- 2005-11-30 CR CR8108A patent/CR8108A/es not_active Application Discontinuation
- 2005-11-30 CO CO05121509A patent/CO5640150A2/es not_active Application Discontinuation
- 2005-12-12 MA MA28652A patent/MA27854A1/fr unknown
- 2005-12-29 NO NO20056236A patent/NO20056236L/no unknown
-
2006
- 2006-09-29 US US11/536,785 patent/US20080248036A1/en not_active Abandoned
- 2006-09-29 US US11/537,310 patent/US20070036753A1/en not_active Abandoned
- 2006-09-29 US US11/537,560 patent/US20070148178A1/en not_active Abandoned
- 2006-09-29 US US11/537,553 patent/US20070036790A1/en not_active Abandoned
- 2006-09-29 US US11/537,527 patent/US20070071748A1/en not_active Abandoned
- 2006-09-29 US US11/536,947 patent/US20070025999A1/en not_active Abandoned
- 2006-09-29 US US11/537,313 patent/US20070036754A1/en not_active Abandoned
- 2006-09-29 US US11/536,931 patent/US20070071718A1/en not_active Abandoned
- 2006-09-29 US US11/537,542 patent/US20070148177A1/en not_active Abandoned
- 2006-09-29 US US11/537,543 patent/US20070071749A1/en not_active Abandoned
- 2006-09-29 US US11/536,881 patent/US20070154483A1/en not_active Abandoned
- 2006-09-29 US US11/536,908 patent/US20070160608A1/en not_active Abandoned
- 2006-09-29 US US11/537,281 patent/US20070031413A1/en not_active Abandoned
-
2007
- 2007-06-14 US US11/763,288 patent/US20080160029A1/en not_active Abandoned
- 2007-06-14 US US11/763,263 patent/US7622115B2/en not_active Expired - Lifetime
- 2007-06-26 JP JP2007167859A patent/JP2007326860A/ja not_active Withdrawn
- 2007-11-06 US US11/935,897 patent/US20080166351A1/en not_active Abandoned
-
2008
- 2008-05-27 US US12/127,733 patent/US20080279860A1/en not_active Abandoned
- 2008-05-29 US US12/129,446 patent/US20090053216A1/en not_active Abandoned
- 2008-06-13 US US12/139,186 patent/US20080248049A1/en not_active Abandoned
- 2008-06-13 US US12/138,611 patent/US20080241148A1/en not_active Abandoned
- 2008-06-30 US US12/164,324 patent/US20090010881A1/en not_active Abandoned
- 2008-07-14 US US12/172,448 patent/US20080267968A1/en not_active Abandoned
- 2008-07-15 US US12/173,764 patent/US20080292630A1/en not_active Abandoned
- 2008-07-25 US US12/179,929 patent/US20090010883A1/en not_active Abandoned
- 2008-07-25 US US12/180,249 patent/US20080292631A1/en not_active Abandoned
- 2008-11-12 AU AU2008243227A patent/AU2008243227A1/en not_active Abandoned
-
2009
- 2009-03-31 US US12/415,599 patent/US20090191215A1/en not_active Abandoned
- 2009-05-15 US US12/466,536 patent/US20090246173A1/en not_active Abandoned
- 2009-10-08 US US12/576,085 patent/US20100226880A1/en not_active Abandoned
- 2009-12-29 RU RU2009149451/15A patent/RU2519669C2/ru not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,414 patent/US20110123494A1/en not_active Abandoned
- 2011-02-25 JP JP2011040742A patent/JP2011144188A/ja not_active Withdrawn
-
2012
- 2012-01-20 US US13/355,205 patent/US20130028862A1/en not_active Abandoned
- 2012-09-04 US US13/602,619 patent/US20130195847A1/en not_active Abandoned
-
2013
- 2013-06-04 JP JP2013118313A patent/JP2013224301A/ja not_active Withdrawn
- 2013-12-19 US US14/134,121 patent/US20140178369A1/en not_active Abandoned
-
2014
- 2014-03-13 RU RU2014109776/15A patent/RU2014109776A/ru not_active Application Discontinuation
- 2014-03-13 RU RU2017109912A patent/RU2017109912A/ru not_active Application Discontinuation
- 2014-05-20 IL IL232718A patent/IL232718A0/en unknown
- 2014-11-20 IL IL235814A patent/IL235814A0/en unknown
-
2015
- 2015-01-15 US US14/597,754 patent/US20150359881A1/en not_active Abandoned
- 2015-11-09 JP JP2015219785A patent/JP2016074681A/ja not_active Withdrawn
-
2016
- 2016-03-25 US US15/080,897 patent/US20160304594A1/en not_active Abandoned
- 2016-06-30 US US15/198,769 patent/US9795672B2/en not_active Expired - Lifetime
- 2016-07-04 IL IL246594A patent/IL246594A0/en unknown
-
2017
- 2017-08-04 JP JP2017152048A patent/JP2018012705A/ja not_active Withdrawn
- 2017-09-14 US US15/705,006 patent/US20180221473A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210134A patent/JP2019055965A/ja active Pending
-
2019
- 2019-06-25 US US16/452,144 patent/US20190307881A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/781,281 patent/US20200171148A1/en not_active Abandoned
- 2020-04-06 JP JP2020068079A patent/JP2020121984A/ja active Pending
- 2020-09-25 US US17/033,141 patent/US20210015918A1/en not_active Abandoned
-
2023
- 2023-03-14 US US18/183,467 patent/US20230218755A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8108A (es) | Tratamiento con anticuerpos anti-vegf | |
PH12014502507A1 (en) | Anti-angiogenesis therapy for the treatment of breast cancer | |
EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
HUP0301877A2 (hu) | Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek | |
TW200635608A (en) | Aβ antibodies for use in improving cognition | |
DE602005023488D1 (de) | Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
EP1572972A4 (en) | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES | |
EP3064509A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
SI1615952T1 (sl) | Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
HK1112941A1 (en) | Use of a33 antigens and jam-it a33 | |
DK1641828T3 (da) | Anti-HGF-R-antistoffer og deres anvendelse | |
NO20076241L (no) | Terapier for vaskulaere sykdommer | |
DK1348029T3 (da) | Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme | |
ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
DE602004023183D1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
CO6612209A2 (es) | Terapia antia-agiogénesis para el tratamiento de cáncer de mama previamente tratado | |
AU2018256601A1 (en) | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer | |
ATE490981T1 (de) | Criptospezifische antikörper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |